Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 9, 2009, Pages 1239-1244

  Tuettenberg, Jochen ^a   Grobholz, Rainer ^b   Seiz, Marcel ^a   Brockmann, Marc A ^a   Lohr, Frank ^a   Wenz, Frederik ^a   Vajkoczy, Peter ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anti angiogenic chemotherapy; COX II inhibitor; Distant recurrence; Glioblastoma; Metronomic chemotherapy; Temozolomide

Indexed keywords

CELECOXIB; GADOLINIUM PENTETATE; ROFECOXIB; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPERIMENTAL STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 68649120407     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0565-9     Document Type: Article

References (42)

1. S Bao Q Wu S Sathornsumetee 2006 Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Res 66 7843 7848
2. L Bello G Carrabba C Giussani 2001 Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo Cancer Res 61 7501 7506
3. MA Brockmann A Papadimitriou M Brandt 2003 Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4 Clin Cancer Res 9 4578 4585
4. MA Brockmann U Ulbricht K Gruner 2003 Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors Neurosurgery 52 1391 1399 (discussion 1399)
5. MA Brockmann A Giese K Mueller 2007 Preoperative thrombocytosis predicts poor survival in patients with glioblastoma efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma Neuro Oncol 9 335 342
6. T Browder CE Butterfield BM Kraling 2000 Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 1878 1886
7. PC Burger PJ Dubois SC Schold Jr 1983 Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme J Neurosurg 58 159 169
8. EL Chang S Akyurek T Avalos 2007 Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma Int J Radiat Oncol Biol Phys 68 144 150
9. A Chi AD Norden PY Wen 2007 Inhibition of angiogenesis and invasion in malignant gliomas Expert Rev Anticancer Ther 7 1537 1560
10. R Coras A Holsken S Seufert 2007 The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion Mol Cancer Ther 6 1745 1754
11. A Eberhard S Kahlert V Goede 2000 Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies Cancer Res 60 1388 1393
12. C Folkins S Man P Xu 2007 Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors Cancer Res 67 3560 3564
13. S Gately R Kerbel 2001 Antiangiogenic scheduling of lower dose cancer chemotherapy Cancer J 7 427 436
14. F Ghiringhelli C Menard PE Puig 2007 Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 641 648
15. A Giese T Kucinski U Knopp 2004 Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma J Neurooncol 66 351 360
16. R Grobholz MH Bohrer M Siegsmund 2000 Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma Pathol Res Pract 196 277 284
17. D Hanahan G Bergers E Bergsland 2000 Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice J Clin Invest 105 1045 1047
18. FH Hochberg A Pruitt 1980 Assumptions in the radiotherapy of glioblastoma Neurology 30 907 911
19. J Holash PC Maisonpierre D Compton 1999 Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1994 1998
20. P Juni L Nartey S Reichenbach 2004 Risk of cardiovascular events and rofecoxib: cumulative meta-analysis Lancet 364 2021 2029
21. Y Kakeji BA Teicher 1997 Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents Invest New Drugs 15 39 48
22. MK Kang SK Kang 2007 Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma Stem Cells Dev 16 837 847
23. PJ Kelly C Daumas-Duport DB Kispert 1987 Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms J Neurosurg 66 865 874
24. RS Kerbel BA Kamen 2004 The anti-angiogenic basis of metronomic chemotherapy Nat Rev Cancer 4 423 436
25. G Klement S Baruchel J Rak 2000 Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 105 R15 R24
26. G Klement P Huang B Mayer 2002 Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts Clin Cancer Res 8 221 232
27. P Kunkel U Ulbricht P Bohlen 2001 Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2 Cancer Res 61 6624 6628
28. K Lamszus MA Brockmann C Eckerich 2005 Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin Clin Cancer Res 11 4934 4940
29. A Maity N Pore J Lee 2000 Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia Cancer Res 60 5879 5886
30. AD Norden GS Young K Setayesh 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787
31. U Oppitz D Maessen H Zunterer 1999 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation Radiother Oncol 53 53 57
32. S Pennacchietti P Michieli M Galluzzo 2003 Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 347 361
33. DA Reardon JN Rich HS Friedman 2006 Recent advances in the treatment of malignant astrocytoma J Clin Oncol 24 1253 1265
34. PF Rijken HJ Bernsen JP Peters 2000 Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis Int J Radiat Oncol Biol Phys 48 571 582
35. A Scheda JK Finjap J Tuettenberg 2007 Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma Tumori 93 31 36
36. R Stupp WP Mason MJ van den Bent 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996
37. BA Teicher EA Sotomayor ZD Huang 1992 Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease Cancer Res 52 6702 6704
38. J Tuettenberg R Grobholz T Korn 2005 Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme J Cancer Res Clin Oncol 131 31 40
39. J Tuettenberg C Friedel P Vajkoczy 2006 Angiogenesis in malignant glioma-a target for antitumor therapy? Crit Rev Oncol Hematol 59 181 193
40. P Vajkoczy P Knyazev A Kunkel 2006 Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival Proc Natl Acad Sci USA 103 5799 5804
41. W Wick M Platten M Weller 2001 Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta J Neurooncol 53 177 185
42. W Wick U Naumann M Weller 2006 Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma Curr Pharm Des 12 341 349